Science

Platform & Technology

Cancer Drug: Powerful, Yet Devastating

Cancer Treatments: Powerful — But Historically Limited by Systemic Toxicity

Cancer drugs are essential tools used across many tumor types, but most conventional agents cannot reliably distinguish cancer cells from healthy tissue. As a result, patients may face severe side effects, organ damage, and dose-limiting toxicities. Despite decades of innovation, few approaches have matched the broad applicability of small-molecule therapies—leaving clinicians with treatments that are indispensable yet imperfect, where fighting cancer can also compromise the body’s ability to heal.

Lahjavida Bio aims to change this.

Rather than modifying existing paradigms, we are establishing an entirely new one — a novel therapeutic class.  We are creating a first- and best-in-class small-molecule Dye–Drug Conjugate (DDC) platform designed to change existing paradigms by concentrating therapeutics in tumors and enabling controlled payload activation to improve efficacy and safety across a broad range of solid tumors. This new therapeutic class is engineered for deeper tumor penetration, lower systemic toxicity, and scalable manufacturing—and is protected by broad IP across dyes, linkers, and DDCs.

Introducing Dye-Drug Conjugates (DDCs): A First-in-Class Advancement in Precision Oncology

Lahjavida Bio’s DDC platform is a next-generation small-molecule delivery system engineered to fundamentally improve how cancer therapies behave inside the body. Each DDC functions as an intelligent, tumor-seeking therapeutic — remaining inert in circulation, homing selectively to malignant tissue, and activating only after entering cancer cells.

Every DDC consists of three modular, purpose-built components:

1

Targeting Moiety (Proprietary NIR Dye) Tumor-Selective Uptake via Multiple Biological Mechanisms

Our proprietary heptamethine NIR dye acts as a molecular homing beacon for cancer cells. Tumor selectivity is driven primarily by OATP overexpression, which facilitates preferential uptake, along with two additional tumor-specific mechanisms supported in the literature:

  • Altered mitochondrial and lysosomal physiology that enhances dye retention
  • Reduced efflux activity (ABCG2) in tumor cells, allowing intracellular accumulation

Together, these mechanisms create a robust and multi-pathway targeting system that enables selective accumulation of Lahjavida’s DDCs in cancer cells while sparing normal tissues.

2

Cleavable Linker (Val-Cit-Based Architecture)

A highly stable, serum-protected linker keeps the therapeutic inactive during circulation. Once internalized into the acidic, enzyme-rich tumor microenvironment, the linker is cleaved to release the payload precisely where it is needed.

3

Cytotoxic Payload (Clinically Validated Agents)

Potent oncology payloads such as SN-38, MMAE, and doxorubicin remain fully inactive until released inside the target cell. Lahjavida Bio is advancing multiple payload classes through preclinical efficacy studies to demonstrate broad applicability and strong translational potential.

This modularity of the platform enables rapid optimization across cancer types, payloads, and linkers, positioning Lahjavida Bio to develop a pipeline of first- and potentially best-in-class small-molecule targeted therapies with significantly reduced systemic toxicity.

The Results

Lahjavida Bio’s DDC platform represents a new class of precision oncology therapeutics — purpose-built to expand treatment options, improve tolerability, and accelerate development timelines for some of the most difficult-to-treat cancers.

Significant Safety Advantage

Lower systemic toxicity in preclinical models

Tumor-specific activation

Demonstrated through in vivo imaging and biodistribution studies

Streamlined, scalable small-molecule CMC

Avoiding the manufacturing, cost, and complexity challenges of biologic ADCs

Our DDC platform leverages small-molecule tumor-targeting dyes with OATP-mediated uptake, enabling:

  • Selective and targeted accumulation of our payloads in cancer cells
  • Release of active cytotoxic payloads where they are needed most
  • A simplified, scalable, and cost-efficient manufacturing process
  • The potential for faster development timelines than antibody approaches

While still in preclinical development, our mission is clear: To help patients fight cancer with treatments designed to target the disease — not the patient’s quality of life.

Partner with us
How It works

Turning Tumor Biology Into a Therapeutic Advantage

Lahjavida Bio’s Dye-Drug Conjugates (DDCs) transform well-understood cancer pharmacology into a highly targeted, small-molecule delivery system. Each DDC is engineered to stay inert in circulation, selectively enter tumor cells, release its payload only where needed, and spare healthy tissues.

01

Circulation — Safe and Inactive in the Bloodstream

Each DDC is designed as an inactive prodrug. While in systemic circulation, it remains stable and non-toxic, minimizing exposure to healthy organs and enabling higher tolerated doses.

02

Targeting — Tumor-Selective Uptake

Lahjavida’s proprietary NIR dye acts as a molecular homing signal that exploits multiple tumor-specific biological differences to achieve selective uptake:

  • OATP Overexpression (Primary MOA): Most solid tumors upregulate OATP transporters, enabling preferential internalization of the dye while healthy tissues largely exclude it.
  • Reduced Efflux (ABCG2): Many tumors exhibit diminished ABCG2 efflux activity, allowing DDCs to remain inside cancer cells rather than being pumped out — further enhancing selective retention.
  • Tumor-Specific Organelle Differences: Distinct mitochondrial and lysosomal environments in cancer cells support enhanced dye accumulation and intracellular trafficking.

Together, these complementary potential mechanisms drive robust tumor targeting and minimal uptake in normal tissue, forming the biological foundation for Lahjavida’s precision-driven DDC platform.

03

Activation — Precision Release Inside Tumor Cells

Once internalized, the tumor microenvironment completes the delivery process.
Low pH and Cathepsin B in tumor lysosomes cleave the enzyme cleavable linker (or next-generation variants), releasing the active drug precisely where it can have the greatest therapeutic effect.

04

Destruction — Killing Cancer From Within

The liberated payload—such as SN-38, MMAE, or doxorubicin—binds to its intracellular target (DNA, topoisomerase, tubulin), destroying tumor cells from the inside out.
Because activation is localized, systemic toxicity is dramatically reduced.

05

Theranostic Capability — Real-Time, Deep-Tissue Visualization

The NIR dye is inherently fluorescent, enabling real-time visualization of tumor uptake and retention. This provides a built-in theranostic feature uncommon among precision-oncology platforms. The dye’s near-infrared properties allow penetration and imaging of tissues up to ~4 inches deep, supporting noninvasive assessment of delivery, localization, and temporal drug distribution.

Why It Matters

See The Difference

Tumor-Agnostic Potential

A platform engineered for tumor-selective delivery across a wide range of cancers with high unmet need

De-Risked Chemistry

Uses FDA-validated linkers and clinically proven payloads.

Faster, Simpler Manufacturing

Fully synthetic, small-molecule production with no biologics, no cell culture, and no extensive cold-chain burden.

First- and Potential Best-in-Class Modality

Precision targeting, modular design, and strong early safety signals position DDCs as a next-generation alternative to large-molecule ADCs.

In-vivo efficacy - Doxorubicin DDC

Tumor volume (day 33)

Study Groups
Untreated (n=7)
Doxorubicin-DDC (n=7; 300 mg/kg)
Doxorubicin-HCL (n=6; 39 mg/kg)

Cumulative dose difference is molecular weight difference between the conjugate and the drug

*** p<0.0002

4-fold less toxic

SN-38

Cumulative dose over 22 days:

240mg

24% weight loss

Mice body weight(g)
Final Weight

Biomaterials. 2014 Oct;35(31): 8854-8866cal

SN-38-DDC

Cumulative dose over 28 days:

240mg

5.5% weight loss

Mice body weight(g)
Final Weight

Noble Labs, MD

7-fold less toxic

Doxorubicin

Cumulative dose over 28 days:

37.5mg

32% weight loss

Mice body weight(g)
Final Weight

Genes Cancer, 2011 Oct, 2(10): 985-992

Doxorubicin-DDC

Cumulative dose over 28 days:

240mg (4.5% higher payload)

4.5% weight loss

Mice body weight(g)
Final Weight

Noble Labs, MD

Irinotecan is the pro-drug form of SN-38

Streamlined, scalable small-molecule CMC

Feature DDC (Dye–Drug Conjugates) ADC (Antibody–Drug Conjugates)
Core scaffold Fully synthetic small molecules (dye + linker + payload) Large biologic (mAb) + linker + payload
Molecular size & heterogeneity Low MW, typically single defined species; easier to characterize High MW, glycosylated, heterogeneous; DAR distribution and glycoforms to control
Expression system & biologics CMC None – chemical synthesis only Requires mammalian cell line, upstream & downstream biologics CMC
Conjugation chemistry Standard small-molecule chemistry; scalable; fewer critical quality attributes Complex bioconjugation, site-specific or stochastic; requires tight control of DAR
Formulation & stability Typically stable as lyophilized or solution; no cold chain required in many cases Often requires cold chain; protein stability, aggregation & deamidation risks
Analytical package Small-molecule analytics (LC–MS, NMR, purity, stability); relatively straightforward release testing Full biologics + conjugate analytics: HCP, aggregates, DAR, charge variants, glycan mapping
Manufacturing footprint Single synthetic route; can use standard API CMOs; relatively low COGS Biologic drug-substance plant + conjugation facility; high capex and COGS
Scale-up risk Lower - well-understood synthetic chemistry and unit operations Higher - bioreactor scale-up, cell line stability, supply-chain complexity
Overall CMC burden Lowest among the four (especially vs ADCs) Highest (biologic + conjugate)